Home›Rheumatology› Tebentafusp provides modest survival benefit and manageable safety profile in metastatic uveal melanoma
Tebentafusp provides modest survival benefit and manageable safety profile in metastatic uveal melanomaTrial Shows Tebentafusp Offers Survival Benefit for Metastatic Uveal Melanoma
Frontiers in MedicinePublished June 17, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that tebentafusp offers modest survival benefit in metastatic uveal melanoma despite low response rates.
This systematic review and meta-analysis evaluates the efficacy and safety of tebentafusp in patients with metastatic uveal melanoma, based on data from 631 patients. The analysis synthesized outcomes including overall survival (OS), progression-free survival (PFS), and various response rates.
Key findings include an overall survival of 21.3 months and a progression-free survival of 3.6 months. The objective response rate was 0.09 (95% CI, 0.06 to 0.13) and the disease control rate was 0.27 (95% CI, 0.20 to 0.36). While response rates are low, the authors suggest tebentafusp may offer a modest but potentially meaningful survival benefit for this patient population.
Safety data indicate that any grade cytokine release syndrome (CRS) occurred in 0.88 (95% CI, 0.84 to 0.91) of patients, while any grade treatment-related adverse events (trAEs) occurred in 0.98 (95% CI, 0.75 to 1.00). Grade 3 or higher trAEs were reported in 0.41 (95% CI, 0.17 to 0.71) of patients. Adverse events are generally considered manageable and controllable.
The authors note limitations including the need for larger sample sizes and multi-center randomized controlled trials to confirm these findings. Clinical application is currently limited by the lack of large-scale comparative data.
How this fits prior evidence
This meta-analysis addresses a gap in evidence regarding tebentafusp monotherapy for metastatic uveal melanoma. It extends prior coverage that noted tebentafusp combined with SBRT showed disease control in a single case and provides broader data on its safety profile, specifically noting manageable adverse events. It does not directly address the liver-directed therapy mentioned in previous findings.
A systematic review and meta-analysis looked at the effectiveness of tebentafusp in 631 patients with metastatic uveal melanoma. The study focused on how well the treatment worked to keep the cancer from progressing and how long it helped patients live.
The results showed an average overall survival of 21.3 months and a progression-free survival of 3.6 months. While the objective response rate was low at 0.09, the drug showed a disease control rate of 0.27. These findings suggest that while many patients do not see a major reduction in tumor size, the treatment may still offer a meaningful benefit for some.
Regarding safety, most side effects were reported as manageable and controllable. The study noted an 88% rate for any grade cytokine release syndrome and a 98% rate for other treatment-related events. However, serious cases of cytokine release syndrome were rare at 2%. Because this was a meta-analysis, more large-scale trials are needed to confirm these results before they can change standard care.
How effective is tebentafusp for metastatic uveal melanoma?
The study found that tebentafusp provides a modest but potentially meaningful survival benefit. While the objective response rate was 0.09 and progression-free survival was 3.6 months, the overall survival was recorded at 21.3 months. These results suggest some benefit despite lower rates of direct tumor shrinkage.
What are the side effects of tebentafusp?
Most treatment-related adverse events were manageable and controllable. The study reported an 88% rate for any grade cytokine release syndrome and a 98% rate for other treatment-related events. Serious cases of cytokine release syndrome occurred in only about 2% of patients.
Is tebentafusp a new standard of care?
The evidence is currently limited because the study was a meta-analysis and not a large, multi-center randomized controlled trial. More research with larger sample sizes is needed to fully determine how this treatment should be used in clinical practice.
ObjectiveTo evaluate efficacy and safety of tebentafusp in patients with metastatic uveal melanoma.MethodA systematic search was conducted in five databases (Pubmed, Embase, Web of Science, Scopus, and the Cochrane Library) to find articles that evaluate the effectiveness of tebentafusp in patients with metastatic uveal melanoma, from the establishment of the databases to October 13, 2025. Additionally, clinical trials were searched on clinicaltrials.gov. Meta-analyses were performed to evaluate the frequencies of progression-free survival (PFS), overall survival (OS), partial response (PR), stable disease (SD), progressive disease (PD), objective response rate (ORR), disease control rate (DCR), Cytokine release syndrome (CRS) and treatment-related adverse events (trAEs).ResultsA total of six studies were initially enrolled, involving 850 participants. Among them, 631 patients with evaluable uveal melanoma who received tebentafusp treatment were ultimately included in this meta-analysis (mean age, 60.56 years; 425 [50%] men). The median OS and PFS were 21.3 months and 3.6 months, respectively. The PR, SD, PD,ORR and DCR were 0.09 [95% confidence interval (CI), 0.05 to 0.14], 0.39 (95% CI, 0.35 to 0.43), 0.79 (95% CI, 0.32 to 0.97), 0.09 (95% CI, 0.06 to 0.13) and 0.27 (95% CI, 0.20 to 0.36), respectively. The any grade cytokine release syndrome rate, grade ≥ 3 cytokine release syndrome rate, any grade trAEs rate and grade ≥ 3 trAEs rate were 0.88 (95% CI, 0.84 to 0.91), 0.02 (95% CI, 0.01 to 0.06), 0.98 (95% CI, 0.75 to 1.00) and 0.41 (95% CI, 0.17 to 0.71), respectively. The most common adverse reactions include pyrexia 0.83 (95% CI, 0.79 to 0.86), nausea 0.58 (95% CI, 0.42 to 0.73), fatigue 0.54 (95% CI, 0.38 to 0.70), pruritus 0.72 (95% CI, 0.65 to 0.78), chills 0.60 (95% CI, 0.47 to 0.71), dry skin 0.43 (95% CI, 0.25 to 0.63), hypotension 0.41 (95% CI, 0.36 to 0.45).ConclusionThe research results show that tebentafusp exhibits modest but potentially meaningful survival benefit despite low response rates for metastatic uveal melanoma patients. Although adverse events often occur, such as cytokine release syndrome of grade three or above, they are usually manageable and controllable. Given the limitations of this study, it is crucial to conduct further multi-center randomized controlled trials and increase the sample size to further verify our results.Systematic review registrationPROSPERO: CRD420251234508. Available from https://www.crd.york.ac.uk/PROSPERO/view/CRD420251234508.
